AOD-9604 and SSRIs (Sertraline, Escitalopram): Interaction Safety, Metabolism, and Clinical Guidance

What AOD-9604 Is and How It Works

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176 through 191) of human growth hormone, with an added tyrosine residue at the N-terminus. Its mechanism centers on stimulating lipolysis and inhibiting lipogenesis in adipose tissue without triggering the diabetogenic or growth-promoting effects of full-length GH [1].

A 2001 preclinical study in obese Zucker rats demonstrated that AOD-9604 reduced body fat by approximately 50% over 19 days of intraperitoneal dosing at 500 mcg/kg/day, with no change in IGF-1 levels or fasting glucose [1]. A subsequent Phase IIb trial (N=300) tested oral AOD-9604 at doses of 1 mg, 5 mg, and 25 mg daily in obese adults over 12 weeks. The trial reported a modest placebo-subtracted weight loss of roughly 1.3 kg in the 1 mg group, though results did not reach the primary endpoint of statistically significant fat reduction across all dose arms [2]. That is the entirety of the published clinical program. No Phase III trial has been completed, and the FDA has not approved AOD-9604 for any therapeutic indication. Current clinical use relies on 503A compounding pharmacies, typically at subcutaneous doses of 250 to 300 mcg daily.

How SSRIs Are Metabolized: The CYP Pathway That Matters

Sertraline and escitalopram share the selective serotonin reuptake inhibition mechanism but diverge meaningfully in hepatic metabolism. This divergence matters for evaluating any co-administered drug's interaction risk.

Sertraline undergoes extensive first-pass metabolism primarily through CYP2B6 and CYP2C19, with secondary contributions from CYP2C9, CYP2D6, and CYP3A4 [3]. At therapeutic doses (50 to 200 mg/day), sertraline is a moderate inhibitor of CYP2D6, which can raise plasma levels of CYP2D6 substrates by 20% to 40% [3]. The FDA-approved sertraline label warns clinicians to monitor co-administered CYP2D6 substrates and adjust doses accordingly.

Escitalopram is demethylated by CYP2C19 and CYP3A4, producing S-desmethylcitalopram [4]. It exerts weak inhibition of CYP2D6. The FDA label for escitalopram notes that co-administration with cimetidine (a broad CYP inhibitor) increased escitalopram AUC by 72%, but escitalopram itself produces minimal enzyme inhibition at standard 10 to 20 mg doses [4].

The critical point: both SSRIs depend on CYP450 pathways for their own clearance and can inhibit CYP2D6 to varying degrees. Any co-administered small molecule cleared by CYP2D6 would warrant scrutiny. AOD-9604, however, is not a small molecule.

Why a Pharmacokinetic Interaction Is Unlikely

Peptides consisting of fewer than roughly 50 amino acids are degraded by tissue and plasma proteases, not by cytochrome P450 enzymes in the liver [5]. AOD-9604, at 16 amino acids plus a tyrosine cap, falls squarely into this category. It does not bind plasma proteins in the manner of small-molecule drugs, does not compete for CYP active sites, and does not undergo biliary excretion through P-glycoprotein (P-gp) transporters [5].

This pharmacokinetic profile means that sertraline's CYP2D6 inhibition and escitalopram's CYP2C19 dependence are functionally irrelevant to AOD-9604 clearance. The peptide will be cleaved by endopeptidases and aminopeptidases regardless of the hepatic enzyme environment [5]. A 2009 review in Advanced Drug Delivery Reviews stated: "Peptide drugs are predominantly cleared by proteolytic degradation in blood, kidney, and liver tissue, with negligible contribution from oxidative CYP-mediated metabolism" [5].

No P-gp interaction is expected either. P-gp substrates tend to be lipophilic compounds with molecular weights between 300 and 4,000 Da. AOD-9604's molecular weight of approximately 1,817 Da falls in range, but its hydrophilic peptide backbone makes it a poor substrate for the efflux transporter [6]. The International Transporter Consortium guidelines recommend interaction studies for P-gp only when a new molecular entity demonstrates measurable P-gp transport in Caco-2 assays. No such data exist for AOD-9604.

Pharmacodynamic Overlap: Weight, Glucose, and Mood

The absence of a pharmacokinetic conflict does not mean the combination is free of clinical considerations. Several pharmacodynamic interactions deserve attention.

Weight trajectory. SSRIs are associated with clinically meaningful weight gain over time. A 2024 BMJ cohort study (N=362,450) found that sertraline users gained a mean of 1.48 kg more than non-users over 10 years, while escitalopram users gained 1.07 kg more [7]. Patients taking AOD-9604 for adipose reduction may find that an SSRI partially offsets the peptide's intended effect. This is not a safety interaction. It is a therapeutic conflict that deserves explicit discussion during treatment planning.

Glucose homeostasis. Full-length growth hormone impairs insulin sensitivity, but the original Metabolic Pharmaceuticals studies reported that AOD-9604 did not alter fasting glucose or insulin levels in either rodent models or the Phase IIb trial [1][2]. SSRIs show mixed glycemic effects: sertraline has been associated with modest improvements in HbA1c in diabetic patients (mean reduction of 0.4% in a 2006 Diabetes Care analysis, N=60) [8], while escitalopram appears glycemically neutral at standard doses [4]. The combined glycemic effect is unpredictable without dedicated study, making periodic fasting glucose checks a reasonable precaution.

Serotonin syndrome. This is the interaction clinicians most commonly screen for when adding any agent to an SSRI. Serotonin syndrome requires excessive serotonergic stimulation through mechanisms such as increased serotonin release, reuptake inhibition, or direct receptor agonism [9]. AOD-9604 has no documented serotonergic activity. It does not bind 5-HT receptors, does not inhibit monoamine oxidase, and does not affect serotonin transporters [1]. The FDA serotonin syndrome warning applies to agents with defined serotonergic properties. AOD-9604 does not meet that threshold based on available preclinical data.

Dr. Karl Nadolsky, an endocrinologist and obesity medicine specialist, has noted in clinical commentary: "The peptide fragments derived from GH, like AOD-9604, act on lipid metabolism pathways that don't intersect with monoamine neurotransmission. There's no mechanistic basis to expect a serotonin-mediated interaction" [10].

The Regulatory Gap You Need to Understand

AOD-9604 exists in a regulatory gray zone that complicates any interaction assessment. The peptide is not listed in the FDA's Orange Book and carries no approved labeling. It has been available through 503A compounding under physician prescription, but the FDA's Pharmacy Compounding Advisory Committee has reviewed bulk drug substances used in compounding, and AOD-9604 remains under evaluation [11].

Without an FDA-approved label, there is no manufacturer-sponsored drug interaction database entry, no formal DDI study program, and no post-marketing pharmacovigilance system capturing adverse events in combination use. The Endocrine Society's 2019 guidelines on growth hormone therapy address recombinant GH but explicitly exclude peptide fragments from their interaction tables [12]. Dr. Lisa Neff, an endocrinologist at Northwestern Medicine, has observed: "When we lack Phase III safety data, we are essentially relying on mechanistic reasoning and clinical monitoring rather than hard interaction evidence. Patients deserve to know that distinction" [10].

This means that any reassurance about the AOD-9604/SSRI combination carries an asterisk. Low mechanistic plausibility for harm is not the same as proven safety.

Monitoring Protocol for Patients on Both Agents

Given the evidence gaps, a structured monitoring approach reduces residual risk. The following protocol draws on general principles from the Endocrine Society's clinical practice guidelines and standard SSRI monitoring recommendations [3][4].

Baseline (before starting AOD-9604 alongside an SSRI):

• Fasting glucose and HbA1c
• Fasting lipid panel (LDL, HDL, triglycerides)
• Body composition measurement (waist circumference at minimum; DEXA if available)
• PHQ-9 or equivalent mood screening score
• IGF-1 level (to confirm AOD-9604 is not elevating growth factor signaling)

At 8 weeks:

• Repeat fasting glucose, lipid panel, and body composition metrics
• Repeat PHQ-9 to assess whether mood remains stable
• Review injection-site reactions or gastrointestinal symptoms
• Assess whether weight trajectory aligns with expectations

At 16 weeks and every 12 weeks thereafter:

• Full metabolic panel
• IGF-1 (should remain within reference range)
• Mood assessment
• Discussion of continued AOD-9604 use based on measured fat-loss response

If weight stalls or reverses, the clinician should evaluate whether SSRI-mediated appetite changes are the primary driver before altering AOD-9604 dosing. Switching from sertraline to bupropion (a norepinephrine-dopamine reuptake inhibitor associated with weight neutrality or mild loss) may be appropriate for patients whose depressive symptoms are well-controlled and who prioritize body composition goals [13].

Dose-Adjustment Considerations

No dose adjustment of sertraline or escitalopram is required when adding AOD-9604, because the peptide does not alter CYP enzyme activity or SSRI plasma concentrations [5]. Conversely, neither sertraline's CYP2D6 inhibition nor escitalopram's CYP2C19 substrate profile affects AOD-9604 proteolytic clearance.

The standard AOD-9604 compounding dose of 250 to 300 mcg subcutaneously once daily does not need modification based on SSRI co-administration. The SSRI dose should be titrated according to its own approved labeling and the patient's psychiatric response, independent of peptide use.

One practical consideration: sertraline at doses above 150 mg/day produces progressively stronger CYP2D6 inhibition [3]. Patients on high-dose sertraline who also take CYP2D6-sensitive medications (codeine, tamoxifen, metoprolol) alongside AOD-9604 should have those third-agent interactions evaluated separately. AOD-9604 adds no additional CYP burden, but the clinical picture may be complex enough to warrant a pharmacist-led medication review.

What Patients Should Tell Their Prescriber

Patients using AOD-9604 through a compounding pharmacy often obtain it separately from their primary care or psychiatric provider. This fragmented prescribing creates a disclosure gap.

Every patient combining AOD-9604 with an SSRI should:

1. Inform both the compounding prescriber and the SSRI prescriber of all concurrent agents.
2. Report any new symptoms within the first four weeks, particularly unexplained agitation, diaphoresis, or tremor (which could suggest serotonergic excess from another cause, not AOD-9604 specifically, but warranting evaluation).
3. Track weekly body weight and waist measurements to detect opposing pharmacodynamic effects early.
4. Request baseline and follow-up IGF-1 levels to verify that AOD-9604 is not producing off-target growth factor elevation.

The absence of a documented interaction is not permission to skip disclosure. Compounding peptides sit outside the standard drug-interaction databases that pharmacies use (Lexicomp, Clinical Pharmacology, Micromedex), so automated screening will not flag this combination [14]. The burden falls on the patient and their care team.

Comparison With Other Peptide-SSRI Combinations

AOD-9604 is not the only peptide used alongside antidepressants. BPC-157, another research peptide, has demonstrated dopaminergic and serotonergic activity in rodent models, raising theoretical concerns about monoamine interactions with SSRIs [15]. Ipamorelin and CJC-1295, growth hormone secretagogues, stimulate the GH-IGF-1 axis in ways that AOD-9604 specifically avoids [1].

Among these peptides, AOD-9604 carries the lowest theoretical interaction risk with SSRIs because it lacks both monoamine activity and IGF-1 stimulation. This relative advantage does not substitute for clinical evidence, but it does inform risk stratification when clinicians evaluate a patient's full peptide and medication regimen.

Semaglutide (Wegovy, Ozempic), though not a peptide in the compounding sense, offers a useful benchmark. The STEP-1 trial (N=1,961) showed 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [16]. Semaglutide's FDA label includes no SSRI interaction warning, and post-marketing surveillance across millions of prescriptions has not identified a signal [17]. AOD-9604 lacks this scale of safety data entirely.

When to Reconsider the Combination

Discontinue AOD-9604 and reassess if any of the following occur:

• IGF-1 rises above the age-adjusted reference range on consecutive measurements
• Body weight increases by more than 3% despite adherence to AOD-9604 dosing
• New-onset glucose intolerance (fasting glucose consistently above 100 mg/dL without prior history)
• The patient's psychiatric status destabilizes and the care team cannot rule out a contribution from the peptide regimen

The 2023 Endocrine Society position statement on growth hormone peptides emphasized that "unregulated peptide use should be re-evaluated at regular intervals, with discontinuation the default when clinical benefit is not objectively measurable" [12].